Nephrology Daily Report: 01/23/2024

A Phase 3 randomized, double-blind placebo-controlled study investigated the effect of veverimer in 1480 patients with chronic kidney disease (eGFR of 20-40 mL/min/1.73 m2) and metabolic acidosis (serum bicarbonate of 12-20 mEq/L) and found that treatment with veverimer did not significantly slow CKD progression compared to placebo (1). The primary endpoint event occurred in 149/741 in the veverimer group and 148/739 in the placebo group (hazard ratio, 0.99; 95% CI, 0.8 to 1.2; P=0.90). The study was conducted in 35 countries and funded by Tricida, Inc. (VALOR-CKD ClinicalTrials.gov number, NCT037102).

Reference

Tangri N, Mathur VS, Bushinsky DA, Klaerner G, Li E, Parsell D, Stasiv Y, Walker M, Wesson DE, Wheeler DC, Perkovic V, Inker LA. VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of Chronic Kidney Disease in Patients with Metabolic Acidosis. J Am Soc Nephrol. 2024 Jan 23. doi: 10.1681/ASN.0000000000000292. Epub ahead of print. PMID: 38261535.